Table 2.
The clinical characteristics and urokinase gene 3′-UTR gene polymorphism and its activity.
| C/C (n = 82) | C/T (n = 9) | P value | |
|---|---|---|---|
| Male gender (%) | 42 (51.8%) | 7 (77.8%) | 0.121 |
| Age of onset (yrs) | 52.5 ± 15.7 | 51.4 ± 25.2 | 0.847 |
| Age of biopsy (yrs) | 58.2 ± 15.4 | 53.9 ± 25.0 | 0.463 |
| Follow-up period (yrs) | 9.6 ± 6.0 | 7.8 ± 5.8 | 0.390 |
| BMI (Kg/M2) | 24.7 ± 3.6 | 24.0 ± 3.3 | 0.557 |
| MBP (mmHg) | 98.6 ± 12.2 | 101.5 ± 24.2 | 0.553 |
| Albumin (mg/dL) | 2.5 ± 0.6 | 2.7 ± 0.5 | 0.338 |
| Cholesterol (mg/dL) | 347.7 ± 137.3 | 298.9 ± 113.3 | 0.307 |
| Triglyceride (mg/dL) | 236.3 ± 165.0 | 161.2 ± 119.5 | 0.189 |
| Crinitial (mg/dL) | 1.3 ± 1.1 | 1.4 ± 1.1 | 0.788 |
| DUPinitial (g/day) | 7.0 ± 8.2 | 7.1 ± 4.7 | 0.974 |
| CCrinitial (mL/min) | 87.6 ± 41.2 | 81.0 ± 45.6 | 0.655 |
| PT (second) | 11.2 ± 0.8 | 11.6 ± 0.8 | 0.290 |
| aPTT (second) | 27.0 ± 5.2 | 30.0 ± 3.2 | 0.144 |
| Crfinal (mg/dL) | 3.3 ± 4.3 | 1.2 ± 0.4 | 0.150 |
| DUPfinal (g/day) | 2.6 ± 3.5 | 1.1 ± 1.3 | 0.197 |
| CCrfinal (mL/min) | 52.1 ± 39.2 | 76.4 ± 26.7 | 0.075 |
| Proteinuria ≧ 3.5 g/day | 28 (34.1%) | 3 (33.3%) | 0.838 |
| Hematuria | 46 (56.1%) | 4 (44.4%) | 0.374 |
| Lower leg edema | 69 (84.1%) | 7 (77.8%) | 0.451 |
| Urine uPA (ng/mL) | 6.17 ± 4.68 | 6.06 ± 5.37 | 0.962 |
BMI: body mass index; MBP: mean blood pressure; DUP: daily urinary protein excretion; CCr: creatinine clearance. All data are presented as mean ± SD; urine uPA: urine urokinase plasminogen activator. There were only 28 urine samples collected from patients with C/C (n = 22) and C/T genotypes (n = 6) of urokinase gene 3′-UTR gene polymorphism for the functional study of urine uPA.